EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa , randomized, double‐blind, efficacy, and safety study

Jacob M van Laar, Alejhandra Lei, Mary Safy-Khan, Joachim Almquist, Graham Belfield, Karl Edman, Lisa Öberg, Bastian R Angermann, Inken Dillmann iD, Pia Berntsson, Damla Etal, Ian Dainty und 9 weitere

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13624 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Jacob M van Laar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine and Dermatology, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Neth…. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral corticosteroid use is limited by side effects, some caused by off‐target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 is a selective, nonsteroidal glucocorticoid receptor modulator. The efficacy, safety, and tolerability of AZD9567 and prednisolone were assessed in a phase IIa study. Anti‐inflammatory mechanism of action was also evaluated in vitro in monocytes from healthy donors. In this randomized, double‐blind, parallel‐group, multicenter study, patients with active rheumatoid arthritis were randomized 1:1 to AZD9567 40 mg or prednisolone 20 mg once daily orally for 14 days. The primary end point was change from baseline in DAS28‐CRP at day 15. Secondary end points included components of DAS28‐CRP, American College of Rheumatology (ACR) response criteria (ACR20, ACR50, and ACR70), and safety end points, including serum electrolytes. Overall, 21 patients were randomized to AZD9567 ( n = 11) or prednisolone ( n = 10), and all completed the study. As anticipated, AZD9567 had a similar efficacy profile to prednisolone, with no clinically meaningful (i.e., >1.0) difference in change from baseline to day 15 in DAS28‐CRP between AZD9567 and prednisolone (least‐squares mean difference: 0.47, 95% confidence interval: −0.49 to 1.43). Similar results were observed for the secondary efficacy end points. In vitro transcriptomic analysis showed that anti‐inflammatory responses were similar for AZD9567, prednisolone, and dexamethasone. Unlike prednisolone, AZD9567 had no effect on the serum sodium:potassium ratio. The safety profile was not different from that of prednisolone. Larger studies of longer duration are required to determine whether AZD9567 40 mg may in the future be an alternative to prednisolone in patients with inflammatory disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansPrednisoloneTreatment OutcomeAnti-Inflammatory AgentsDouble-Blind MethodMethotrexateIndazolesPyridines

Substanzen

PrednisoloneAntirheumatic AgentsAnti-Inflammatory AgentsMethotrexateAZD9567IndazolesPyridines

Autor:innen und Institutionen

  • Division of Internal Medicine and Dermatology, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Patient Safety BioPharmaceuticals, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Translational Genomics, Discovery Biology SE, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Mechanistic and Structural Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Inken Dillmann

Zitieren

APA

van Laar, J. M., Lei, A., Safy-Khan, M., Almquist, J., Belfield, G., Edman, K., Öberg, L., Angermann, B. R., Dillmann, I., Berntsson, P., Etal, D., Dainty, I., Astbury, C., Belvisi, M. G., Nemes, S., Platt, A., Prothon, S., Samuelsson, S., Svanberg, P., …, & SEMRA study group (2023). AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa , randomized, double‐blind, efficacy, and safety study. Clinical and Translational Science. https://doi.org/10.1111/cts.13624

Vancouver

van Laar JM, Lei A, Safy-Khan M, Almquist J, Belfield G, Edman K, et al. AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa , randomized, double‐blind, efficacy, and safety study. Clinical and Translational Science. 2023. doi:10.1111/cts.13624

BibTeX
@article{vanLaar2023,
  author = {van Laar, Jacob M and Lei, Alejhandra and Safy-Khan, Mary and Almquist, Joachim and Belfield, Graham and Edman, Karl and Öberg, Lisa and Angermann, Bastian R and Dillmann, Inken and Berntsson, Pia and Etal, Damla and Dainty, Ian and Astbury, Carol and Belvisi, Maria G and Nemes, Szilárd and Platt, Adam and Prothon, Susanne and Samuelsson, Sara and Svanberg, Petter and Keen, Christina and SEMRA study group, SEMRA study group},
  title = {AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa , randomized, double‐blind, efficacy, and safety study},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13624}
}
Kostenlos starten →